IMDX (Insight Molecular Diagnostics Inc.) stock: $2.49, $81.5M market cap, $17.8M cash, $63.7M EV, $100.9M fully diluted market cap. Lead program: donor-derived cell-free DNA test (Kidney Transplant Rejection). Data from Fully Diluted's biotech stocks database.
What they do
We are a pioneering diagnostics technology company. Our mission is to expand access to novel molecular diagnostic testing, most immediately in the transplanted organ rejection testing category. We are developing molecular diagnostic test kits designed to empower our customers to run their own tests in-house to participate in the patient-care value chain, which is counter-positioned with the send-out-testing central laboratory model.
Stage not disclosed · ActiveModality: diagnostic (kitted in vitro diagnostic test)
Partnerships Bio-Rad Laboratories (10-year global strategic partnership, April 2024, to co-develop and commercialize RUO and IVD kitted transplant products; Bio-Rad also an equity investor)
Indications
Kidney transplant (multiple tissue/organ types planned)(Stage not disclosed)
Status note IVD kitted transplant product for clinical use; clinical trial started in 2025 in conjunction with the IVD submission. Kitted tests require FDA marketing authorization (U.S.) and IVDR approval (EU) before clinical use.
GraftAssureIQ
Stage not disclosed · ActiveModality: diagnostic (kitted RUO test)
Partnerships Bio-Rad Laboratories (10-year global strategic partnership, April 2024)
Indications
Kidney transplant(Stage not disclosed)
Status note RUO kitted transplant test being developed and commercialized under the Bio-Rad collaboration.
GraftAssureCore
Stage not disclosed · ActiveModality: diagnostic (kitted transplant test)
Partnerships Bio-Rad Laboratories (10-year global strategic partnership, April 2024)
Indications
Kidney transplant(Stage not disclosed)
Status note Named as a current focus of R&D alongside GraftAssureIQ and GraftAssureDx; iMDx depends on the Bio-Rad collaboration for development and commercialization of kitted transplant products.
Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.